Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| MiNa Therapeutics | MTL-CEBPA in combination with Keytruda (pembrolizumab) | advanced solid tumors | initiation and first patient treated in phase 1/1b trial |
| TargoVax SA | ONCOS-102 in combination with Keytruda (pembrolizumab) | advanced anti-PD1 checkpoint inhibitor (CPI) refractory melanoma | patient enrollment completed in phase 1 trial |
| HUYA Bioscience International | HBI-3000 | cardioversion of atrial fibrillation | completion of phase 1 trial |
| Dynacure | DYN101 | myotubular and centronuclear myopathies | first patient dosed in phase 1/2 trial |
| Allergan plc Editas Medicine |
AGN-151587 (EDIT-101) | Leber congenital amaurosis 10 (LCA10) | first patient dosed in phase 1/2 trial |
| Arrowhead Pharma | ARO-HSD | patients with NASH or suspected NASH | first patients dosed in phase 1/2 trial |
| DiscGenics | IDCT, allogeneic, injectable discogenic cell therapy | degenerative disc disease | completed enrollment in phase 1/2 trial |
| Novus Therapeutics | OP0201 | pediatrics with acute otitis media | completed enrollment in phase 2a trial |
| VBI Vaccines | VBI-1901 in combination with either GM-CSF or AS01B, (GlaxoSmithKline) | recurrent GBM | first patient dosed in the second study arm of phase 2a trial |
| Innovent Biologics | IBI375 (pemigatinib) | advanced cholangiocarcinoma with FGFR2 fusions or rearrangements | first patients dosed in phase 2 trial |
| Neuraly | NLY01 | Parkinson’s disease | first patient dosed in phase 2 trial |
| Moderna | mRNA-1647 | cytomegalovirus | completed enrollment in phase 2 trial |
| American BriVision | ABV-1505 | adult attention-deficit hyperactivity disorder | initiation of phase 2 trial |
| EpicentRx | AIM-001 | tumors | IND approved by FDA |
| Prevail Therapeutics | PR006 | frontotemporal dementia patients with GRN mutation | IND approved by FDA |
| Ayala Pharmaceuticals | AL101 | recurrent or metastatic adenoid cystic carcinoma | Fast Track designation granted by FDA |
| Genentech | Esbriet (pirfenidone) | adults with unclassifiable interstitial lung disease | Breakthrough Therapy Designation granted by FDA |
| Sanofi | Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) | adults with multiple myeloma who have had two previous therapies including lenalidomide and a protease inhibitor | approved by the FDA |
